Shorter radiation regimen safe, effective in soft tissue sarcoma
Sarcoma, a rare type of cancer of the soft tissues (for example, muscle, nerves, fat, or fibrous tissue) or bone, affects about 13,000 people of all ages in the United States each year. Many people with a soft tissue sarcoma diagnosis receive a 5-week course of radiation therapy (daily Monday through Friday). Four to five weeks after that, the tumour is removed in surgery.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed 5-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.
"Shortening the radiation therapy from 5 weeks to 5 days has been a very meaningful change for patients," said lead author Dr Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. "Five weeks of daily treatments is a burdensome commitment for patients. The daily back-and-forth can be expensive and time-consuming, and it can really interfere with work, school or parenting. So finding a way to safely shorten the radiation treatment is a significant advancement in improving the quality of care for patients with hard-to-treat cancers like sarcoma."
Researchers enrolled 52 adults at UCLA diagnosed with a soft tissue sarcoma of the limbs or trunk—where these tumours most commonly occur—that was localized and had not spread to other parts of the body. The participants underwent a condensed form of radiation therapy for 5 days, followed by surgery. The team then analyzed and followed the cohort for an average of 2 1/2 years.
They found less than 6% of the patients with at least 2 years of follow-up on the clinical trial had a recurrence of their tumor, which is on par with studies using the conventional 5-week regimen, Kalbasi said.
"The main reason we treat sarcoma patients with radiation before surgery is to prevent the tumor from recurring where it was removed," said Kalbasi, who is also a member of the Jonsson Cancer Center. "As an added benefit, in some cases, it can cause the tumor to shrink. So far it appears that the 5-day treatment is working just as well as the 5-week treatment."
Along with studying tumour recurrence rates, researchers also closely examined the severity of wound complications. Sarcoma surgery often requires a large incision to remove the tumor and can by itself result in wound complications. Adding radiation before surgery can slow the healing process even more. The team wanted to make sure the condensed 5-day treatment didn't make wound complications worse.
"In the long term, having radiation before surgery lowers the chance of side effects like swelling, joint stiffness and fibrosis, that are big contributors to quality of life," Kalbasi said. "But this comes at a trade-off with a higher rate of wound complications immediately after surgery. The good news is that our five-day treatment did not increase the chance for wound issues after surgery compared to the conventional 5-week treatment."
Not only did the researchers find that wound complication were virtually the same for the two therapies, but they also identified a new set of biomarkers that could indicate how likely someone will be to encounter significant wound complications.
By using a DNA swab from each participant to test for mutations, the team found that they could identify microRNA-disrupting genetic biomarkers that are associated with the risk of wound complications.
"We know from experience that different patients respond to the same amount of radiation in different ways, and we have always believed that it is due to the patient's personal response to radiation," said study co-author Dr Joanne Weidhaas, a professor of radiation oncology and director of translational research at the David Geffen School of Medicine at UCLA, who led the biomarker studies. "This type of biomarker lets us know upfront who may or may not have a high risk of wound complications and can potentially help us determine the best type of treatment to offer for patients. Having this information upfront is a big advantage, which can really advance personalized medicine."
In the 2 years since the study began, the team also noticed a rapid rise in the number of patients coming to UCLA, a high-volume sarcoma centre, for radiation treatment before surgery. Nearly half of the study participants travelled more than 100 miles to UCLA for radiation treatment. Past studies have shown treating sarcomas at a high-volume centre with the expertise of a multidisciplinary sarcoma team is associated with improved outcomes.
The 5-day radiation therapy regimen may not only be preferred by people undergoing the treatment, but it will also result in more people having access to care at high-volume centres that specialize in treating such rare cancer, Kalbasi said.
To further validate the study's findings, the team plans to continue to follow the cohort for at least 5 years to see if, in terms of cancer control and longer-term side effects, the 5-day radiation treatment continues to be just as safe and effective as the traditional five-week treatment. The team has also expanded the clinical trial to include patients who are also receiving chemotherapy before surgery.
The study was published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
for further references log on to:
Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D. Nelson, Sarah Dry, Jackie Hernandez, Bartosz Chmielowski, Arun S Singh, Susan V Bukata, Nicholas Bernthal, Michael L Steinberg, Joanne B Weidhaas, Fritz C. Eilber. A Phase 2 Trial of Five-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clinical Cancer Research, 2020; clincanres.3524.2019
DOI: 10.1158/1078-0432.CCR-19-3524
